AR106945A2 - Compuestos de isoindolina y composiciones farmacéuticas de los mismos - Google Patents

Compuestos de isoindolina y composiciones farmacéuticas de los mismos

Info

Publication number
AR106945A2
AR106945A2 ARP160103716A ARP160103716A AR106945A2 AR 106945 A2 AR106945 A2 AR 106945A2 AR P160103716 A ARP160103716 A AR P160103716A AR P160103716 A ARP160103716 A AR P160103716A AR 106945 A2 AR106945 A2 AR 106945A2
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
heterocyclyl
aryl
same
Prior art date
Application number
ARP160103716A
Other languages
English (en)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR106945A2 publication Critical patent/AR106945A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto que tiene la fórmula (3), o una sal, solvato, prodroga o estereoisómero farmacéuticamente aceptable del mismo, en donde: X es C(=O) o CH₂; m es un entero de 0, 1, 2, ó 3; R⁵ y R⁶ son cada uno, de manera independiente: hidrógeno, halo, C₁₋₆ alquilo, oxo, -NO₂, C₁₋₆ alcoxi, -Z-C₁₋₆ alquilo, C₀₋₆ alquil-(heteroarilo de 5 a 10 miembros), C₀₋₆ alquil-(heterociclilo de 5 a 6 miembros), C₀₋₆ alquil-OH, C₀₋₄ alquil-NH₂, -NHCO-C₁₋₆ alquilo, -OR²¹, o -(CH₂-Y)₀₋₂-(heteroarilo de 5 a 10 miembros), en donde Z es S o SO₂; Y es CH₂, NH, u O; en donde R²¹ es C₆₋₁₀ arilo, heteroarilo de 5 a 10 miembros, heterociclilo de 5 a 6 miembros, o -CO(CH₂)₀₋₂R²², en donde el arilo, heteroarilo, y heterociclilo están cada uno opcionalmente sustituido con uno o más C₁₋₆ alquilo; R²² es -NH₂ o heterociclilo de 5 a 6 miembros; en donde cada heteroarilo y heterociclilo anterior está opcionalmente sustituido con uno o más C₁₋₆ alquilo; y en donde el alquilo o alcoxi anterior puede estar opcionalmente sustituido con uno o más entre: halógeno; ciano; nitro; amino; C₁₋₆ alquilidendioxi; C₁₋₆ alcoxi, el mismo opcionalmente sustituido con uno o más halógenos; o C₁₋₆ alquiltio, el mismo opcionalmente sustituido con uno o más halógenos; R⁷ es -COR⁷¹ o -PO(OR⁷²)(OR⁷³); R⁷¹ es C₁₋₁₀ alquilo, C₆₋₁₀ arilo, o heterociclilo de 5 a 6 miembros; en donde el alquilo, arilo, heterociclilo pueden estar opcionalmente sustituidos con uno o más de amino, C₁₋₆ alquilamino, di(C₁₋₆ alquil)amino, o -COOR⁷⁴; y R⁷², R⁷³, y R⁷⁴ son cada uno, de manera independiente, hidrógeno o C₁₋₁₀ alquilo.
ARP160103716A 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos AR106945A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10947508P 2008-10-29 2008-10-29

Publications (1)

Publication Number Publication Date
AR106945A2 true AR106945A2 (es) 2018-03-07

Family

ID=41328433

Family Applications (6)

Application Number Title Priority Date Filing Date
ARP090104177 AR074001A1 (es) 2008-10-29 2009-10-29 Compuestos de isoindolina y composiciones farmaceuticas y uso para tratamiento de cancer
ARP160103716A AR106945A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103713A AR106943A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103712A AR106942A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103715A AR106944A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103802A AR106963A2 (es) 2008-10-29 2016-12-12 Compuestos de isoindolina y composiciones farmacéuticas de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090104177 AR074001A1 (es) 2008-10-29 2009-10-29 Compuestos de isoindolina y composiciones farmaceuticas y uso para tratamiento de cancer

Family Applications After (4)

Application Number Title Priority Date Filing Date
ARP160103713A AR106943A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103712A AR106942A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103715A AR106944A2 (es) 2008-10-29 2016-12-02 Compuestos de isoindolina y composiciones farmacéuticas de los mismos
ARP160103802A AR106963A2 (es) 2008-10-29 2016-12-12 Compuestos de isoindolina y composiciones farmacéuticas de los mismos

Country Status (30)

Country Link
US (6) US8129375B2 (es)
EP (3) EP3354646A1 (es)
JP (3) JP5603876B2 (es)
KR (3) KR101696938B1 (es)
CN (2) CN102264720B (es)
AR (6) AR074001A1 (es)
AU (1) AU2009311477B2 (es)
BR (1) BRPI0919942B1 (es)
CA (2) CA2741299C (es)
CL (1) CL2011000957A1 (es)
CO (1) CO6361916A2 (es)
DK (1) DK2358697T3 (es)
ES (2) ES2662407T3 (es)
HR (1) HRP20151366T1 (es)
HU (1) HUE026105T2 (es)
IL (9) IL212435A (es)
MX (2) MX2011004470A (es)
NI (1) NI201100082A (es)
NZ (1) NZ592425A (es)
PE (2) PE20140963A1 (es)
PL (1) PL2358697T3 (es)
PT (1) PT2358697E (es)
RU (1) RU2527952C2 (es)
SG (2) SG10201703508QA (es)
SI (1) SI2358697T1 (es)
SM (1) SMT201600025B (es)
TW (1) TWI469974B (es)
UA (1) UA107783C2 (es)
WO (1) WO2010053732A1 (es)
ZA (1) ZA201102941B (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
BR112015026006B1 (pt) 2013-04-17 2022-10-18 Signal Pharmaceuticals, Llc Uso de um composto em combinação com um fármaco imunomodulador imid® para tratamento ou prevenção de um câncer, composição farmacêutica e kit compreendendo os referidos compostos
KR102299801B1 (ko) 2013-12-06 2021-09-10 셀진 코포레이션 미만성 거대 b-세포 림프종, 다발성 골수종, 및 골수암의 치료를 위한 약물 효능을 결정하는 방법
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3131588B1 (en) * 2014-04-14 2025-11-05 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
WO2016057503A1 (en) * 2014-10-07 2016-04-14 Celgene Corporation Use of biomarkers for predicting clinical sensitivity to cancer treatment
EP3214081B1 (en) 2014-10-30 2020-07-08 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
CN107428734A (zh) 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
AU2017206039B2 (en) * 2016-01-08 2021-03-25 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
SG11201805777QA (en) * 2016-01-08 2018-08-30 Celgene Corp Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
UA123168C2 (uk) * 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN111892577B (zh) * 2016-10-11 2023-07-07 阿尔维纳斯运营股份有限公司 用于雄激素受体靶向降解的化合物和方法
IL304982A (en) 2016-11-01 2023-10-01 Arvinas Operations Inc PROTACS Targeted Tau-Protein and Related Methods of Use
LT3689868T (lt) 2016-12-01 2023-12-27 Arvinas Operations, Inc. Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
JP7679173B2 (ja) 2016-12-23 2025-05-19 アルビナス・オペレーションズ・インコーポレイテッド Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
AU2018215212B2 (en) 2017-01-31 2022-06-02 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
PL3590924T3 (pl) 2017-02-28 2022-01-24 Kangpu Biopharmaceuticals, Ltd. Nowa pochodna izoindoliny oraz jej kompozycja farmaceutyczna i zastosowanie
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN118206529A (zh) 2017-09-04 2024-06-18 C4医药公司 二氢苯并咪唑酮
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
JP7458324B2 (ja) 2018-04-23 2024-03-29 セルジーン コーポレイション 置換された４－アミノイソインドリン－１，３－ジオン化合物、及びリンパ腫の治療のためのそれらの使用
SG11202011568XA (en) 2018-05-23 2020-12-30 Celgene Corp Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
RU2695326C1 (ru) * 2018-06-05 2019-07-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Противоопухолевое средство для лечения рака предстательной железы в форме саше
US11530219B2 (en) 2018-06-29 2022-12-20 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
MX2021000309A (es) 2018-07-10 2021-04-12 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-dion a y su uso en el tratamiento de enfermedades dependientes del dedo de zinc 2 de la familia ikaros (ikzf2).
JP7086272B2 (ja) * 2018-08-16 2022-06-17 コリア リサーチ インスティテュート オブ ケミカル テクノロジー イソインドリン－１－オン誘導体、同じものを調製する方法、およびがんを予防するまたは処置するための有効な構成要素として同じものを含む医薬組成物
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
AU2019391016B2 (en) 2018-12-03 2025-05-29 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use
WO2020114482A1 (zh) 2018-12-06 2020-06-11 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021012524A (es) 2019-04-12 2021-11-12 C4 Therapeutics Inc Degradadores triciclicos de ikaros y aiolos.
US11564913B2 (en) 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
JP7656589B2 (ja) 2019-08-26 2025-04-03 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
WO2021069705A1 (en) * 2019-10-09 2021-04-15 Monte Rosa Therapeutics Isoindolinone compounds
CN119019369A (zh) 2019-10-17 2024-11-26 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
AU2020375794A1 (en) * 2019-10-28 2022-05-19 Celgene Corporation Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies
JP2023507590A (ja) * 2019-12-17 2023-02-24 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質の動員および／または分解を調節する化合物
CN118059104A (zh) 2019-12-19 2024-05-24 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
CA3173118A1 (en) * 2020-03-31 2021-10-07 Orum Therapeutics, Inc. Neodegrader conjugates
JP2023524599A (ja) 2020-05-09 2023-06-12 アルビナス・オペレーションズ・インコーポレイテッド 二官能性化合物を製造する方法、二官能性化合物の超高純度形態、及びそれらを含む剤形
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
TW202214236A (zh) 2020-09-14 2022-04-16 美商亞文納營運公司 用於靶向降解雌激素受體之化合物之結晶及非晶形形式
JP2023542930A (ja) 2020-09-23 2023-10-12 セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド セレブロンタンパク質のモジュレータとしての置換ｎ－（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－５－イル）アリールスルホンアミド類似体
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
CN117242060A (zh) * 2021-01-13 2023-12-15 蒙特罗萨医疗公司 异吲哚啉酮化合物
EP4313047A1 (en) * 2021-03-22 2024-02-07 Monte Rosa Therapeutics, Inc. Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
WO2022219407A1 (en) * 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN117279910A (zh) 2021-04-16 2023-12-22 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
TW202313022A (zh) * 2021-06-03 2023-04-01 南韓商歐倫醫療公司 新降解劑－抗ｃｄ３３抗體綴合物
MX2023014284A (es) * 2021-06-03 2024-02-27 Orum Therapeutics Inc Conjugados de neodegradadores.
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide
TW202330037A (zh) * 2021-09-08 2023-08-01 南韓商歐倫醫療公司 用於抗體藥物綴合物之連接子
CN116082301A (zh) * 2021-11-05 2023-05-09 上海美志医药科技有限公司 具有降解gspt1活性的化合物及其应用
KR102823538B1 (ko) 2021-11-09 2025-06-23 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
WO2023085785A1 (ko) 2021-11-09 2023-05-19 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
WO2023096822A1 (en) * 2021-11-23 2023-06-01 St. Jude Children's Research Hospital, Inc. Substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetamide analogs as modulators of gspt1 and/or ikzf1 protein
AU2022419982A1 (en) * 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2025513877A (ja) 2022-04-14 2025-04-30 ブリストル－マイヤーズ スクイブ カンパニー 新規なｇｓｐｔ１化合物およびその新規な化合物の使用方法
JP2025516873A (ja) * 2022-05-18 2025-05-30 ▲蘇▼州宜▲聯▼生物医▲薬▼有限公司 タンパク質分解剤クラスの生物学的活性化合物を含む抗体薬物複合体及びその調製方法並びに使用
AU2023283735A1 (en) 2022-06-06 2024-10-31 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders
CN119546605A (zh) * 2022-08-01 2025-02-28 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024075080A1 (en) * 2022-10-06 2024-04-11 Orum Therapeutics, Inc. Neodegrader conjugates
KR20240066904A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR20240066906A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
WO2024165075A1 (en) * 2023-02-10 2024-08-15 Nanjing Huanbo Biotechnology Co., Ltd. G protein-coupled receptor kinase 2 (grk2) degradation compounds and use thereof
KR20250133786A (ko) * 2023-02-15 2025-09-08 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 도마이드계 분자 접착제 유도체 및 이의 용도
WO2025016359A1 (zh) * 2023-07-14 2025-01-23 标新生物医药科技(上海)有限公司 戊二酰亚胺基异吲哚啉酮骨架的化合物
WO2025085416A1 (en) * 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
US12496301B2 (en) 2023-12-08 2025-12-16 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DE59207778D1 (de) * 1991-04-17 1997-02-06 Gruenenthal Gmbh Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20110116225A (ko) 2003-12-02 2011-10-25 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
MXPA06012278A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
WO2006053160A2 (en) 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
BRPI0518282A2 (pt) 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
KR20070090227A (ko) 2004-12-01 2007-09-05 셀진 코포레이션 면역조절 화합물을 포함하는 조성물 및 이의 면역결핍성장애의 치료를 위한 용도
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
UA91560C2 (ru) * 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
ES2359162T3 (es) 2005-09-01 2011-05-19 Celgene Corporation Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
BRPI0716092A2 (pt) * 2006-08-30 2013-09-17 Celgene Corp composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP5567339B2 (ja) * 2006-09-15 2014-08-06 セルジーン コーポレイション Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法

Also Published As

Publication number Publication date
US9796698B2 (en) 2017-10-24
IL234168A (en) 2016-07-31
DK2358697T3 (en) 2016-01-25
US20170088538A1 (en) 2017-03-30
CA2957226C (en) 2018-08-14
US8318773B2 (en) 2012-11-27
AR106963A2 (es) 2018-03-07
CN102264720A (zh) 2011-11-30
MX361467B (es) 2018-12-06
EP2985281B1 (en) 2017-12-27
CN102264720B (zh) 2015-03-25
SMT201600025B (it) 2016-02-25
AR106944A2 (es) 2018-03-07
EP2358697A1 (en) 2011-08-24
AU2009311477A1 (en) 2010-05-14
AU2009311477B2 (en) 2014-10-30
PE20140963A1 (es) 2014-08-06
KR20170007531A (ko) 2017-01-18
EP2985281A3 (en) 2016-03-30
US8129375B2 (en) 2012-03-06
AR106943A2 (es) 2018-03-07
CN104744434A (zh) 2015-07-01
JP2014224119A (ja) 2014-12-04
IL234162A (en) 2016-06-30
PL2358697T3 (pl) 2016-04-29
US8222249B2 (en) 2012-07-17
NI201100082A (es) 2011-10-26
JP2012507541A (ja) 2012-03-29
RU2527952C2 (ru) 2014-09-10
IL234166B (en) 2018-04-30
TWI469974B (zh) 2015-01-21
CA2741299C (en) 2017-03-28
JP5603876B2 (ja) 2014-10-08
PE20110547A1 (es) 2011-08-04
HK1154859A1 (zh) 2012-05-04
PT2358697E (pt) 2016-02-03
SG10201703508QA (en) 2017-06-29
ES2662407T3 (es) 2018-04-06
BRPI0919942B1 (pt) 2019-02-19
IL212435A (en) 2015-06-30
ZA201102941B (en) 2012-07-25
ES2559388T3 (es) 2016-02-11
US20160115161A1 (en) 2016-04-28
IL234164A (en) 2016-07-31
IL228597A (en) 2017-01-31
CA2957226A1 (en) 2010-05-14
EP2985281A2 (en) 2016-02-17
IL228597A0 (en) 2013-12-31
NZ592425A (en) 2013-04-26
JP6034924B2 (ja) 2016-11-30
TW201022227A (en) 2010-06-16
US9550766B2 (en) 2017-01-24
EP2358697B1 (en) 2015-10-21
US20100204227A1 (en) 2010-08-12
EP3354646A1 (en) 2018-08-01
RU2011121567A (ru) 2012-12-10
CA2741299A1 (en) 2010-05-14
US9227954B2 (en) 2016-01-05
US20120252843A1 (en) 2012-10-04
SG195613A1 (en) 2013-12-30
IL234163A (en) 2016-06-30
IL234165A (en) 2017-08-31
HRP20151366T1 (hr) 2016-01-15
SI2358697T1 (sl) 2016-02-29
JP5998179B2 (ja) 2016-09-28
JP2015227343A (ja) 2015-12-17
KR20180000750A (ko) 2018-01-03
CL2011000957A1 (es) 2011-09-16
UA107783C2 (en) 2015-02-25
AR074001A1 (es) 2010-12-15
AR106942A2 (es) 2018-03-07
IL234167A (en) 2017-09-28
BRPI0919942A2 (pt) 2014-12-23
WO2010053732A1 (en) 2010-05-14
IL212435A0 (en) 2011-06-30
US20130045976A1 (en) 2013-02-21
CO6361916A2 (es) 2012-01-20
KR101696938B1 (ko) 2017-01-16
HUE026105T2 (en) 2016-05-30
KR20110089162A (ko) 2011-08-04
MX2011004470A (es) 2011-05-31
US20120122865A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
DOP2010000046A (es) Compuestos de biciclolactama sustituida
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR099023A1 (es) Pirazolil-heteroarilamidas como agentes plaguicidas
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
PE20081566A1 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
AR096246A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
ECSP099601A (es) Inhibidores de proteasa de serina
AR107170A1 (es) Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
ECSP099269A (es) Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2018002242A (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
CO6150149A2 (es) Compuestos azabiciclicos como inhibidfores de la recaptacion de monoaminas
PE20081113A1 (es) Inhibidores virales policiclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure